ClinicalTrials.gg

Program

deutetrabenazine

Also written as “SD-809”, “TEV-50717” and “Deutetrabenazine”.

Its studies are mostly in Tourette Syndrome · Huntington Disease · Tardive Dyskinesia · Cerebral Palsy, led by Teva Pharmaceutical Industries.

Furthest: phase 4, since May 15, 202612 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Teva Pharmaceutical Industries120 open or runningphase 4since May 15, 2026Feb 20, 2013none ahead

Also a collaborator on its studies: nuvelution-ts-pharma-inc.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 20, 2013First study: phase 3 study in ChoreaFirst studyNCT01795859 · 90 enrolled · United States, Australia, Canada
  2. Jun 14, 2013Phase 3 study in ChoreaNCT01897896 · 119 enrolled · United States, Australia, Canada
  3. Jul 18, 20142 phase 3 studies in Tardive DyskinesiaNCT02195700, NCT02198794
  4. Nov 12, 2014Phase 3 study in Tardive DyskinesiaNCT02291861 · 298 enrolled · United States, Czechia, Germany and more
  5. Feb 2, 2016Phase 1 study in Tourette SyndromeNCT02674321 · 23 enrolled · United States
  6. Feb 26, 2018Phase 3 study in Tourette SyndromeNCT03452943 · 119 enrolled · United States, Canada, Denmark and more
  7. Jun 12, 20182 phase 3 studies in Tourette SyndromeNCT03567291, NCT03571256
  8. Jan 22, 2019Phase 3 study in Cerebral PalsyNCT03813238 · 63 enrolled · United States, Belgium, Canada and more
  9. Dec 12, 2019Phase 3 study in Cerebral PalsyNCT04200352 · 44 enrolled · United States, Denmark, Israel and more
  10. May 15, 2026Phase 4 study in Huntington DiseaseNCT07601516 · 50 enrolled · China

TargetBeta

SLC18A2 →read by rule
“Synaptic vesicular amine transporter inhibitor; Synaptic vesicular amine transporter inhibitor”ChEMBL 37, by rule

Other programs on SLC18A2

ProgramCompanyFurthest phaseStudies
lisdexamfetamineruleTakedaphase 447
valbenazineruleNeurocrine Biosciencesphase 428

Studies

All 12 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07601516Huntington Disease · China4CompletedOct 24, 202550
NCT04200352Cerebral Palsy · United States, Denmark, Israel and more3TerminatedFeb 14, 202344
NCT03813238Cerebral Palsy · United States, Belgium, Canada and more3CompletedJul 5, 202263
NCT03571256Tourette Syndrome · United States, Argentina, Australia and more3CompletedDec 9, 2019158
NCT03567291Tourette Syndrome · United States, Argentina, Australia and more3TerminatedMay 15, 2020228
NCT03452943Tourette Syndrome · United States, Canada, Denmark and more3CompletedNov 12, 2019119
NCT02674321Tourette Syndrome · United States1CompletedJun 201523
NCT02291861Tardive Dyskinesia · United States, Czechia, Germany and more3CompletedAug 19, 2016298
NCT02198794Tardive Dyskinesia · United States, Czechia, Germany and more3CompletedDec 6, 2019343
NCT02195700Tardive Dyskinesia · United States, Czechia, Poland and more3CompletedMay 2015117
NCT01897896Chorea · United States, Australia, Canada3CompletedAug 21, 2017119
NCT01795859Chorea · United States, Australia, Canada3CompletedDec 5, 201490

How it is read

Names in the registry

  • “SD-809”, 6 entries
  • “TEV-50717”, 5 entries
  • “Deutetrabenazine”, 1 entry

Codes read as this program: TEV50717.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.